Eli Lilly profit misses as vaccines sap U.S. demand for COVID-19 drugs
Reuters
Published Apr 27, 2021 06:43AM ET
Updated Apr 27, 2021 08:16AM ET
(Reuters) -Eli Lilly and Co on Tuesday missed estimates for first-quarter profit and cut the top end of its full-year forecast for adjusted earnings as demand for its COVID-19 antibody therapies took a hit due to the roll-out of vaccines in the United States.
Demand for antibody drugs from Lilly and Regeneron (NASDAQ:REGN) has failed to take off in the United States, given the complexities associated with administering the treatments.
Sales of Lilly's COVID-19 antibody drug, bamlanivimab, also came under pressure after the U.S. government stopped its distribution as a standalone treatment last month on worries that new variants of the virus could be resistant to it.
The drugmaker is now focusing on a combination of bamlanivimab with another treatment, etesevimab.
"COVID-19 therapies are reducing in their need as the virus is being arrested by vaccines in the United States," Lilly's Chief Executive Officer David Ricks said in an interview with CNBC.
Lilly earned $810.1 million from its COVID-19 drugs in the quarter, below estimates of $985 million, according to Guggenheim analysts. Lilly shares fell 4% in premarket trading.
The drugs, which include bamlanivimab as well as its combination with etesevimab, had brought in sales of $871.2 million in the fourth quarter.
The company now expects adjusted full-year earnings of $7.80 to $8 per share from its prior forecast of $7.75 to $8.40 per share.
Sales from COVID-19 drugs are expected in the range of $1 billion to $1.5 billion from $1 billion to $2 billion projected previously.
Excluding items, the company earned $1.87 per share, missing estimates of $2.13 per share, according to IBES data from Refinitiv.
Net earnings fell 7% to $1.36 billion, or $1.49 per share, in the quarter ended March 31.
Get The News You Want
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.